STOCK TITAN
  1. Home
  2. Sec-filings
  3. CADL
  4. [Form 4] Candel Therapeutics, Inc. Insider Trading Activity

Candel Therapeutics (CADL) director receives fully vested 381-option equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Candel Therapeutics director Nicoletta Loggia received a grant of stock options as compensation. The award covers 381 options to buy Candel common stock at an exercise price of $10.30 per share, expiring on June 30, 2036. According to the disclosure, this award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following the grant, Loggia holds 381 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Loggia Nicoletta
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 381 $8.639 $3K
Holdings After Transaction: Stock Option (Right to Buy) — 381 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 381 options Stock option grant to director Nicoletta Loggia
Exercise price $10.30 per share Exercise price of granted stock options
Grant date fair value $8.639 per option Transaction price per option on grant
Expiration date June 30, 2036 Option expiration for this grant
Options after transaction 381 options Total derivative securities held following grant
Underlying shares 381 shares Common shares underlying this option award
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
fully vested financial
"The underlying award quantity is fully vested at time of grant"
in lieu of normal quarterly cash payments financial
"This award has been granted in lieu of normal quarterly cash payments"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Loggia Nicoletta
(Last)(First)(Middle)
C/O CANDEL THERAPEUTICS, INC.
117 KENDRICK ST., SUITE 450
(Street)
NEEDHAM MASSACHUSETTS 02494
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$10.306/30/2026A38107/01/2026(1)06/30/2036Common Stock381$8.639381D
Explanation of Responses:
1. This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
/s/ Charles Schoch, as Attorney-In-Fact for Nicoletta Loggia07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Candel Therapeutics (CADL) director Nicoletta Loggia report on this Form 4?

Nicoletta Loggia reported receiving a grant of 381 stock options to buy Candel Therapeutics common stock. The options are a form of equity compensation awarded instead of normal quarterly cash payments and are fully vested when granted.

How many Candel Therapeutics (CADL) stock options were granted to Nicoletta Loggia?

The filing shows a grant of 381 stock options to Nicoletta Loggia. Each option represents the right to purchase one share of Candel Therapeutics common stock, and the award replaces a normal quarterly cash payment for board service.

What is the exercise price and term of Nicoletta Loggia’s CADL stock options?

The granted stock options have an exercise price of $10.30 per share and expire on June 30, 2036. This means Loggia may choose to buy Candel Therapeutics shares at $10.30 any time before that expiration date, subject to plan terms.

Are Nicoletta Loggia’s new Candel Therapeutics options vested?

Yes. The footnote states the underlying award quantity is fully vested at the time of grant. This means all 381 options are immediately exercisable, rather than vesting over time, and were issued instead of normal quarterly cash compensation.

How many Candel Therapeutics derivative securities does Nicoletta Loggia hold after this grant?

After the reported transaction, Nicoletta Loggia directly holds 381 stock options in Candel Therapeutics. This total reflects the newly granted award and represents her derivative position as shown in this Form 4 filing excerpt.